167 related articles for article (PubMed ID: 38244059)
1. Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review.
Dornisch AM; Zhong AY; Poon DMC; Tree AC; Seibert TM
World J Urol; 2024 Jan; 42(1):56. PubMed ID: 38244059
[TBL] [Abstract][Full Text] [Related]
2. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
Kerkmeijer LGW; Groen VH; Pos FJ; Haustermans K; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; van Vulpen M; Draulans C; van den Bergh L; Isebaert S; van der Heide UA
J Clin Oncol; 2021 Mar; 39(7):787-796. PubMed ID: 33471548
[TBL] [Abstract][Full Text] [Related]
3. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
[TBL] [Abstract][Full Text] [Related]
4. MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
Zapatero A; Roch M; Castro Tejero P; Büchser D; Martin de Vidales C; González S; Rodríguez P; San Jose LA; Celada G; Murillo MT
Br J Radiol; 2022 Mar; 95(1131):20210683. PubMed ID: 34538073
[TBL] [Abstract][Full Text] [Related]
5. Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.
Vigneault E; Mbodji K; Racine LG; Chevrette E; Lavallée MC; Martin AG; Després P; Beaulieu L
Brachytherapy; 2016; 15(6):746-751. PubMed ID: 27743955
[TBL] [Abstract][Full Text] [Related]
6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
7. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.
Tamihardja J; Lawrenz I; Lutyj P; Weick S; Guckenberger M; Polat B; Flentje M
Strahlenther Onkol; 2022 Aug; 198(8):735-743. PubMed ID: 35551434
[TBL] [Abstract][Full Text] [Related]
8. Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: Toxicity in the FLAME randomized controlled trial.
Monninkhof EM; van Loon JWL; van Vulpen M; Kerkmeijer LGW; Pos FJ; Haustermans K; van den Bergh L; Isebaert S; McColl GM; Smeenk RJ; Noteboom J; Walraven I; Peeters PHM; van der Heide UA
Radiother Oncol; 2018 Apr; 127(1):74-80. PubMed ID: 29336835
[TBL] [Abstract][Full Text] [Related]
9. Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy.
Chen WC; Tokita KM; Ravera J; Fu P; Jiang Y; Kaminsky DA; Ponsky L; Ellis RJ
Brachytherapy; 2013; 12(5):422-7. PubMed ID: 23380382
[TBL] [Abstract][Full Text] [Related]
10. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials.
Kee DLC; Gal J; Falk AT; Schiappa R; Chand ME; Gautier M; Doyen J; Hannoun-Levi JM
Cancer Treat Rev; 2018 Nov; 70():265-271. PubMed ID: 30326422
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Asian patients with localized prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience.
Ng IWS; Tey JCS; Soon YY; Tseng MSF; Chen D; Lim KHC
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e386-e391. PubMed ID: 29171166
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial.
Buwenge M; Alitto AR; Cilla S; Capocaccia I; Mazzeo E; Ippolito E; Mantini G; Siepe G; Cavallini L; Valentini V; Deodato F; Morganti AG; Macchia G
Anticancer Res; 2020 Nov; 40(11):6499-6503. PubMed ID: 33109589
[TBL] [Abstract][Full Text] [Related]
14. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
[TBL] [Abstract][Full Text] [Related]
15. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
16. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review.
Feutren T; Herrera FG
Prostate Int; 2018 Sep; 6(3):75-87. PubMed ID: 30140656
[TBL] [Abstract][Full Text] [Related]
17. Tumor-targeted dose escalation for localized prostate cancer using MR-guided HDR brachytherapy (HDR) or integrated VMAT (IB-VMAT) boost: Dosimetry, toxicity and health related quality of life.
Sanmamed N; Lee J; Berlin A; Craig T; Lao B; Rink A; Bayley A; Catton C; Sundaramurthy A; Foltz W; McPartlin A; Ghai S; Astenafu E; Gospodarowicz M; Warde P; Ménard C; Chung P
Radiother Oncol; 2020 Aug; 149():240-245. PubMed ID: 32447033
[TBL] [Abstract][Full Text] [Related]
18. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer.
Groen VH; Haustermans K; Pos FJ; Draulans C; Isebaert S; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; Kerkmeijer LGW; van der Heide UA
Eur Urol; 2022 Sep; 82(3):252-257. PubMed ID: 34953603
[TBL] [Abstract][Full Text] [Related]
20. Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.
Wong WW; Vora SA; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
Cancer; 2009 Dec; 115(23):5596-606. PubMed ID: 19670452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
